These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
617 related articles for article (PubMed ID: 24314118)
21. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913 [TBL] [Abstract][Full Text] [Related]
22. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169 [TBL] [Abstract][Full Text] [Related]
23. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333 [TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML. Guo C; Li J; Steinauer N; Wong M; Wu B; Dickson A; Kalkum M; Zhang J J Biol Chem; 2020 Mar; 295(13):4212-4223. PubMed ID: 32071087 [TBL] [Abstract][Full Text] [Related]
25. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism]. Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793 [TBL] [Abstract][Full Text] [Related]
26. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335 [TBL] [Abstract][Full Text] [Related]
28. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia. Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287 [TBL] [Abstract][Full Text] [Related]
29. AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia. Zhou L; Wang Q; Chen X; Fu L; Zhang X; Wang L; Deng A; Li D; Liu J; Lv N; Wang L; Li Y; Liu D; Yu L; Dou L Exp Hematol; 2017 Feb; 46():62-69. PubMed ID: 27725192 [TBL] [Abstract][Full Text] [Related]
30. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718 [TBL] [Abstract][Full Text] [Related]
32. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia. Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743 [TBL] [Abstract][Full Text] [Related]
33. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661 [TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line. Zhuang WY; Cen JN; Zhao Y; Chen ZX Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926 [TBL] [Abstract][Full Text] [Related]
35. Identification of AML1-ETO modulators by chemical genomics. Corsello SM; Roti G; Ross KN; Chow KT; Galinsky I; DeAngelo DJ; Stone RM; Kung AL; Golub TR; Stegmaier K Blood; 2009 Jun; 113(24):6193-205. PubMed ID: 19377049 [TBL] [Abstract][Full Text] [Related]
36. Transcription of the AML1/ETO chimera is guided by the P2 promoter of the AML1 gene in the Kasumi-1 cell line. Markova EN; Kantidze OL; Razin SV Gene; 2012 Dec; 510(2):142-6. PubMed ID: 22995345 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263 [TBL] [Abstract][Full Text] [Related]
38. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906 [TBL] [Abstract][Full Text] [Related]
39. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Lu Y; Xu YB; Yuan TT; Song MG; Lübbert M; Fliegauf M; Chen GQ Leukemia; 2006 Jun; 20(6):987-93. PubMed ID: 16598301 [TBL] [Abstract][Full Text] [Related]
40. Definition of a small core transcriptional circuit regulated by AML1-ETO. Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]